Phaseline

Companies › Sonnet BioTherapeutics

Sonnet BioTherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SON-1010
Recombinant IL-12 fused to albumin-binding domain (FHAB) for albumin hitchhiking and tumor
IL12Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05352750SON-1010Phase 1Advanced Solid TumorOncologyJun 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

IL12 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.